The notoriously drug-resistant bug MRSA has made headlines for years, but a whole other class of bacteria may prove even more troublesome. These microbes, Gram-negative bacteria, are increasingly a threat—and yet not a single late-stage drug in development specifically targets them. Christian Torres follows one man's quest to get the antibacterial pipeline flowing once again.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Antibiotic control of antibiotic resistance in hospitals: a simulation study
BMC Infectious Diseases Open Access 25 August 2010
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Vincent, J.-L. et al. J. Am. Med. Assoc. 302, 2323–2329 (2009).
Boucher, H.W. et al. Clin. Infect. Dis. 48, 1–12 (2009).
Kallen, A.J., Hidron, A.I., Patel, J. & Srinivasan, A. Infect. Control Hosp. Epidemiol. 31, 528–531 (2010).
Spellberg, B., Powers, J.H., Brass, E.P., Miller, L.G. & Edwards, J.E. Jr. Clin. Infect. Dis. 38, 1279–1286 (2004).
Spellberg, B. et al. Clin. Infect. Dis. 46, 155–164 (2008).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Torres, C. Up against the wall. Nat Med 16, 628–631 (2010). https://doi.org/10.1038/nm0610-628
Issue Date:
DOI: https://doi.org/10.1038/nm0610-628
This article is cited by
-
Increasing consumption of MRSA-active drugs without increasing MRSA in German ICUs
Intensive Care Medicine (2011)
-
Antibiotic control of antibiotic resistance in hospitals: a simulation study
BMC Infectious Diseases (2010)
